ANTISENSE Pharma GmbH

Company

    • Company type:
      • Research & Development
    • Year founded:
    • 1998
    • Employees (at the site):
    • 72
    • Turnover range:
    • <5m EUR
    • Products/services:
    • Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. The agents specifically block the synthesis of key cancer proteins. The lead product AP 12009 - a Transforming Growth Factor-beta2 inhibitor - is in final clinical development for the treatment of high grade glioma as well as in phase I/II clinical trial for the treatment of colorectal carcinoma, pancreatic carcinoma and malignant melanoma. The further product pipeline covers preclinical drug candidates as well as compounds in research and discovery. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award.

    • Core competencies:
    • not available

    • Language skills:
    • English
      French
      German
      Spanish
    • Key Tech / section:
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72: Scientific research and development
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Philippe Calais (Mr.)
      - Management